T-cell acute lymphoblastic leukemia (T-ALL)

T-ALL is usually first suspected from blood tests. A complete blood count (CBC) and a look at the blood under a microscope (blood smear) can show young leukemia cells called blasts. Compared with B-cell ALL, T-ALL more often starts with a very high white blood cell count. Doctors then take a small sample of bone marrow, most often from the back of the hip bone (bone marrow aspiration and biopsy).

Lab tests on the blood and marrow show what kind of leukemia it is. Flow cytometry (immunophenotyping) reads markers on the cells. Markers such as CD3 and CD7 show that the cells are young T cells, not B cells. Chromosome tests (cytogenetics) and gene tests look for changes that help plan treatment. Standard chromosome results often take a week or more, because the cells must first grow in the lab.

Other tests check where the leukemia has spread. A chest X-ray looks for a lump in the middle of the chest, which is more common in T-ALL than in B-cell ALL. A lumbar puncture (spinal tap) checks the fluid around the brain and spinal cord for leukemia cells. A pathologist reads the samples, and a hematologist-oncologist, a doctor who treats blood cancers, may review them too.

Combination chemotherapy is given through induction, consolidation and maintenance phases, with treatment to protect or treat the central nervous system. Specific protocols differ for children, adolescents and adults. Nelarabine is included in some protocols or used for selected relapsed disease.

Allogeneic transplantation may be recommended for persistent MRD, high-risk features or disease that returns after treatment. Many patients with an adequate response complete treatment without a transplant.

Options after relapse are more limited than in B-ALL. B-cell-targeted medicines and CD19 CAR-T products do not directly treat T-lineage leukemia simply because both conditions are called ALL. T-cell-directed cellular therapies are being studied, and clinical trial eligibility is treatment- and center-specific.

When a transplant from a donor is planned, the team usually tests brothers and sisters first. Each full sibling has about a one in four chance of being a full match.

Most patients do not have a matched relative. In the words of NMDP, the U.S. registry, “75% of patients don’t have a fully matched donor in their own family.” The team then searches registries of volunteer donors around the world and banks of donated cord blood. In some transplants, a half-matched parent, child or sibling can also be the donor.

Matching depends on inherited tissue markers called HLA, so a patient is most likely to match someone who shares their ancestry. Every person who joins makes the search a little more likely to succeed, especially for patients from groups that are underrepresented on registries.

Many people with T-ALL are cured, especially children and teens. For a long time, children with T-ALL did worse than children with B-cell ALL. Modern treatment has narrowed that gap, though T-ALL still does slightly less well in most studies. For adults with ALL, the outlook is less hopeful than for children, but the National Cancer Institute notes high cure rates for T-ALL with some intensive treatment plans.

How fast the leukemia responds is one of the strongest signs. Doctors measure tiny leftover amounts of leukemia (measurable residual disease, or MRD). In a large childhood trial, a high MRD level at the end of the first phase of treatment was linked to worse results. Leukemia that is not in remission after the first phase (induction failure) is harder to cure. In adults, European transplant guidance lists high MRD, the early T-cell precursor (ETP) type and some chromosome changes as higher-risk features. It also notes that changes in genes called NOTCH1 or FBXW7 are linked to better results.

T-ALL that comes back is harder to treat. It tends to return sooner than B-cell ALL, and fewer treatments work for it. That is one reason transplant guidance calls for an early transplant consultation when the risk of relapse is high.